RxDoctor Payments Data

Reza Akhtar, MD

Gastroenterology · Oakhurst, NJNPI 1629195748

Payments from drug & device makers

$6,475in general payments, 2019–2025

Across 245 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AbbVie$720
  • Johnson & Johnson$619
  • Pfizer$448
  • Ambu Inc.$388
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$281
  • plus $940 from 19 others

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Travel & lodging$4868%
  • Food & beverage$5,86891%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,475 in reported general payments places this provider in the 75th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$227,215
Medicare patients
787
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$38,656
CreonLipase/Protease/Amylase13$27,947
Mesalamine13$11,001
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,633
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,768
Ursodiol17$1,580
Pantoprazole Sodium115$1,535
Omeprazole38$519
Famotidine25$396
Ondansetron OdtOndansetron24$211
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$204
Dicyclomine Hcl14$157
Metoclopramide Hcl13$123
Hydrocortisone15$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$281$40,42427 claims
AbbVieCreon$720$27,94713 claims
Braintree Laboratories, Inc.Sutab$12$3,63323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Oakhurst

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →